First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

March 29 2022 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series - OnDemand

Date of Release: May 4, 2022

Expiration Date: May 31, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date

Course Description:

Gene fusions involving the RET gene and alterations in the MET gene are established actionable drivers of lung cancer and have FDA-approved therapies available based on the detection of these alterations.  The Mayo Clinic molecular technologies laboratory uses NGS technology to look not only at these hallmark alterations, but many others that may impact clinical management. Pathology, genomics, and emerging information from clinicians and laboratory experts convene to help mold care for these patients.  In this session, 2 cases will be presented – one with a RET fusion and one with a MET exon 14 skipping alteration – with additional genomic and pathological findings that help direct patient management. In addition, the clinical trial data leading to the approvals of these targeted therapies will be presented.

Target Audience:

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic and VICC consortia, and ACMG.

Learning Objectives:

At the conclusion of this session, participants should be able to:

1.            Recall the spectrum of mutations in non-small cell lung cancer

2.            Describe the biological mechanisms of RET and MET alterations in lung cancer

3.            Discuss the implications of RET and MET alterations for clinical patient management

Moderator:

Jason Saliba, PhD

Senior Scientist

Washington University, St. Louis, MO

Presenter(s):

Dr. Aaron Mansfield, MD

Medical Oncologist, Co-Director of Precision Cancer Therapeutics for the Center of Individualized Medicine

Dr. Mansfield is a medical oncologist at Mayo Clinic with a focus on thoracic malignancies and early therapeutics. He is co-director of the Precision Cancer Therapeutics group within the Center for Individualized Medicine. He has played a significant role in clinical trials leading to FDA approval of agents for thoracic malignancies including atezolizumab for small cell lung cancer, pralsetinib for RET-fusion non-small cell lung cancer and the combination of ipilimumab with nivolumab for mesothelioma. His laboratory runs many translational projects to discover and validate biomarkers in thoracic malignancies.

Dr. Kevin Halling, MD, PhD

Molecular Pathologist, Laboratory Director, and Professor in the Division of Laboratory Genetics and Genomics, Mayo Clinic Rochester, MN

Dr. Halling is a molecular pathologist and a Professor in the Division of Laboratory Genetics and Genomics at Mayo Clinic in Rochester, MN.  He received his M.D. and Ph.D. from the University of Kansas and completed an Anatomic and Clinical pathology residency and Clinical Molecular Genetics fellowship at the Mayo Clinic. His primary area of interest is in the development and implementation of molecular diagnostic tests that can be used for the diagnosis and treatment of cancer (solid tumor) patients. Dr. Halling has published over 150 papers that mostly relate to genetic testing of cancer.

Beth Pitel, MS

Senior Developer, Assistant Professor in the Division of Laboratory Genetics and Genomics, Office of Translational Research, Innovation, and Test Development, Mayo Clinic, Rochester, MN

Beth is a Senior Developer involved with the development and maintenance of several testing modalities, including NGS oncology panels, RNAseq, mate pair sequencing, chromosomal microarray, and qPCR.  She leads the Genomics of Oncology Annotation Team (GOAT), a group that creates interpretive resources for the laboratory based on current knowledge in the field of cancer genetics. Beth has worked at Mayo Clinic since 2007 and completed her Master’s degree from the Mayo Graduate School in Biochemistry and Molecular biology in 2015 with foci on cancer biology and bioinformatics. She co-leads the VICC VMTB and is an active member of ClinGen Somatic working group and the Cancer Genomics Consortium.  Beth has co-authored over 30 peer-reviewed manuscripts focusing mainly on cancer genetic alterations and methodologies.

Planning Committee:

Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP 

Continuing Medical Education (CME AMA & CME Other)

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer

ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net